Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
This study has been terminated.
( Terminated due to inadequate rate of accrual. )
Study NCT01202890 Information provided by New Mexico Cancer Care Alliance
First Received on September 14, 2010. Last Updated on June 29, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma
Additional conditions recognized in this trial
Carcinoma
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Additional drug interventions recognized in this trial
Bevacizumab
Doxorubicin
Lenalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
New Mexico Cancer Care Alliance
Celgene Corporation
Back to top of Main Content
